EMA Grants Orphan Drug Designation to QRX003 for Peeling Skin Syndrome
QNRX sits 39% above its 52-week low of $3.25.
Summary
Quoin Pharmaceuticals received EMA Orphan Drug Designation for QRX003 in Peeling Skin Syndrome, adding a European regulatory milestone to its existing US designations. The designation provides 10 years of market exclusivity in Europe upon marketing authorization, along with incentive benefits including scientific advice on study protocols, various fee reductions, and access to EU grants. QRX003 has been granted four Orphan Drug designations by three major regulatory agencies, two Pediatric Rare Disease Designations from the US FDA, and Fast Track Status for both indications in the US. The company is on track to initiate the first formal clinical trial in Peeling Skin Syndrome before year-end. This follows FDA Rare Pediatric Disease and Fast Track designations for the same indication in September, reinforcing the drug's regulatory momentum. The designation strengthens the commercial outlook for QRX003 in a rare disease with no approved therapies.
Updated with an SEC 8-K filing · What changed
Updates
· SEC 8-K — On October 14, 2026, Quoin Pharmaceuticals announced the EMA granted Orphan Drug Designation to QRX003 for Peeling Skin Syndrome, providing 10 years of market exclusivity in Europe upon marketing authorization.
- EMA Orphan Drug Designation provides incentive benefits including scientific advice on study protocols, various fee reductions, and access to EU grants.
- QRX003 has been granted four Orphan Drug designations by three major regulatory agencies, two Pediatric Rare Disease Designations from the US FDA, and Fast Track Status for both indications in the US.
At the time of this announcement, QNRX was trading at $4.53 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $8.3M. The 52-week trading range was $3.25 to $23.50. This news item was assessed with positive market sentiment and an importance score of 7 out of 10. Source: GlobeNewswire.